STOCK TITAN
  1. Home
  2. News
  3. RMTI

Rockwell Medical, Inc. (DE) - RMTI STOCK NEWS

Welcome to our dedicated page for Rockwell Medical (DE) news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Medical (DE) stock.

Rockwell Medical, Inc. (DE), trading under the symbol RMTI, is a leading biopharmaceutical company dedicated to addressing the needs of patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company has positioned itself at the forefront of renal care through its innovative products and services focusing on iron replacement, secondary hyperparathyroidism, and hemodialysis.

One of Rockwell Medical's groundbreaking therapies is Triferic, the first and only FDA-approved drug designed to replace iron and maintain hemoglobin levels in hemodialysis patients with anemia. Triferic works during each dialysis session by replacing the 5-7 mg iron loss that is typical in all patients, thereby maintaining their iron balance. Differing from traditional intravenous (IV) iron products, Triferic binds immediately to transferrin (the body's iron carrier) and is swiftly transported to the bone marrow for incorporation into hemoglobin. This unique mechanism ensures no increase in ferritin (stored iron and inflammation) and eliminates the risks of anaphylaxis, addressing a critical unmet need for functional iron deficiency (FID) in ESRD patients.

Rockwell Medical is also a prominent supplier of dialysis concentrates in the United States. Their diverse product portfolio includes notable brands such as CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate. These products are essential for dialysis providers, helping to ensure that patients receive the necessary treatments for effective dialysis.

The company's commitment to innovation and quality is reflected in its ongoing projects and recent achievements. Rockwell Medical continues to focus on expanding its product line and enhancing its manufacturing processes to meet the evolving needs of the renal care market. Financially, the company maintains a robust position with strategic partnerships and collaborations that further bolster its market presence and capabilities.

For those interested in the latest updates and developments regarding Rockwell Medical, Inc., the company's news section provides current information on performance, events, and significant milestones.

News

Rockwell Medical Continues to Expand its Distribution Capabilities in Western United States

Rhea-AI Summary
Rockwell Medical, Inc. (Nasdaq: RMTI) has entered into a new direct supply agreement with one of the largest health systems in the Mountain West region of the United States. The agreement includes supplying liquid and dry acid and bicarbonate hemodialysis concentrates, cleaning agents, hemodialysis concentrates mixers, and other products. This move aims to enhance distribution capabilities and support dialysis providers in the region, ensuring patients with chronic kidney disease and end-stage renal disease receive high-quality care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News

Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024

Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) will release its first quarter 2024 financial and operational results on May 14, 2024. The Company develops, manufactures, and distributes hemodialysis products globally. A live conference call and webcast will follow the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
-
News

Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda

Rhea-AI Summary
Rockwell Medical (RMTI) announces new distribution agreements with BioNuclear and AMI, expected to generate $1 million in annual revenues. The agreements aim to expand the global reach of hemodialysis products, reinforcing the company's position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
none
News

Rockwell Medical Named 'Great Place to Work' for Second Year in a Row

Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) has been certified as a Great Place to Work® for the second consecutive year, showcasing employee satisfaction and positive work culture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News

Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023

Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) reports record net sales and gross profit for the second consecutive year in 2023, with net sales reaching $83.6 million and gross profit hitting $8.7 million. Achieving profitability on an adjusted EBITDA basis in Q4 2023, the company issues 2024 guidance projecting net product sales between $84 million and $88 million, gross margin between 14% and 16%, and profitability on an adjusted EBITDA basis for the full year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
earnings
-
News

Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024

Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. The conference call will include a discussion of fourth quarter and full-year 2023 operational and financial results followed by Q&A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
News

Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund

Rhea-AI Summary
Rockwell Medical, Inc. (Nasdaq: RMTI) announced the amendment of its loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, deferring principal payments of $8.0 million up to three years. The amendment reduces the Company's need for additional operating capital and enhances its cash balance. The Company also provided preliminary projected fourth quarter and full-year 2023 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News

Rockwell Medical Announces Third Quarter 2023 Results

Rhea-AI Summary
RMTI - Rockwell Medical, Inc. Announces Record Third Quarter 2023 Financial and Operational Results, Expects Profitability in Fourth Quarter. Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, the highest sales generated to-date for the Company. Gross profit for the third quarter of 2023 increased 183% over the same period in 2022. Rockwell Medical reiterates projected 2023 net sales to be between $82.0 million and $86.0 million, an increase of 17% to 18% year-over-year, and projected 2023 gross profit to between $8.0 million and $10.0 million, an increase of 95% to 144% year-over-year. The Company expects to achieve profitability on an adjusted EBITDA basis in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
earnings
-
News

Rockwell Medical Names Jesse Neri as Senior Vice President, Finance

Rhea-AI Summary
Rockwell Medical announces the appointment of Jesse Neri as Senior Vice President, Finance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
none
News

Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Rhea-AI Summary
Rockwell Medical appoints Joan Lau, Ph.D. to its board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
management

FAQ

What is the current stock price of Rockwell Medical (DE) (RMTI)?

The current stock price of Rockwell Medical (DE) (RMTI) is $3.44 as of October 11, 2024.

What is the market cap of Rockwell Medical (DE) (RMTI)?

The market cap of Rockwell Medical (DE) (RMTI) is approximately 107.6M.

What does Rockwell Medical, Inc. specialize in?

Rockwell Medical specializes in products and services for the treatment of end-stage renal disease (ESRD) and chronic kidney disease (CKD), focusing on iron replacement, secondary hyperparathyroidism, and hemodialysis.

What is Triferic?

Triferic is an FDA-approved drug by Rockwell Medical designed to replace iron and maintain hemoglobin levels in hemodialysis patients suffering from anemia.

How does Triferic differ from traditional IV iron products?

Unlike IV iron products, Triferic binds immediately to transferrin upon entering the blood and is transported directly to the bone marrow, minimizing inflammation and eliminating anaphylaxis risks.

What types of dialysis concentrates does Rockwell Medical offer?

Rockwell Medical offers a range of dialysis concentrates, including CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate.

Where is Rockwell Medical's market focus?

Rockwell Medical primarily focuses on the United States market, supplying a comprehensive portfolio of hemodialysis products to dialysis providers.

What recent achievements has Rockwell Medical made?

Rockwell Medical continues to innovate and expand its product offerings, with recent achievements including enhancements to its manufacturing processes and strategic partnerships that strengthen its market position.

What unmet need does Triferic address?

Triferic addresses the significant unmet need of overcoming functional iron deficiency (FID) in end-stage renal disease (ESRD) patients, ensuring effective iron replacement and hemoglobin maintenance during dialysis.

How can I stay updated on Rockwell Medical's latest news?

You can stay updated on Rockwell Medical's latest news by visiting their official website and checking the news section for the most recent information on company performance, events, and developments.

What is Rockwell Medical's financial condition?

Rockwell Medical maintains a robust financial position supported by strategic partnerships and ongoing efforts to expand its product line and enhance manufacturing processes.

How does Rockwell Medical maintain its market relevance?

Rockwell Medical maintains market relevance through continuous innovation, expanding its product portfolio, enhancing manufacturing processes, and forming strategic collaborations and partnerships.

Stock RMTI logo
Rockwell Medical, Inc. (DE)

Nasdaq:RMTI

RMTI Rankings

#4307 Ranked by Market Cap
N/A Ranked by Dividends

RMTI Stock Data

107.61M
31.03M
11.84%
20.77%
1.38%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
WIXOM